CD274 and neoplasm: Common markers of response to immune checkpoint inhibitors, such as programmed cell death ligand 1 (PDL1) expression and tumor mutation burden (TMB) are at times associated with higher responses, yet they have not been applied clinically, given the presence of observed responses in the absence of these markers (16–18).